Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Immune Monitoring on Sipuleucel-T
A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
Status: Enrolling
Updated:  1/3/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Immune Monitoring on Sipuleucel-T
A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
Status: Enrolling
Updated: 1/3/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Immune Monitoring on Sipuleucel-T
A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
Status: Enrolling
Updated:  1/3/2017
Weill-Cornell Medical College
mi
from
New York, NY
Immune Monitoring on Sipuleucel-T
A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
Status: Enrolling
Updated: 1/3/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
A Phase II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Aplidin® as a 3-hour IV Infusion Every 2 Weeks, in Relapsing or Refractory Patients With Androgen-independent Prostate Adenocarcinoma..
Status: Enrolling
Updated:  1/3/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
A Phase II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Aplidin® as a 3-hour IV Infusion Every 2 Weeks, in Relapsing or Refractory Patients With Androgen-independent Prostate Adenocarcinoma..
Status: Enrolling
Updated: 1/3/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
A Phase II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Aplidin® as a 3-hour IV Infusion Every 2 Weeks, in Relapsing or Refractory Patients With Androgen-independent Prostate Adenocarcinoma..
Status: Enrolling
Updated:  1/3/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
A Phase II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Aplidin® as a 3-hour IV Infusion Every 2 Weeks, in Relapsing or Refractory Patients With Androgen-independent Prostate Adenocarcinoma..
Status: Enrolling
Updated: 1/3/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy
Phase I/II Evaluation Magnetic Resonance Imaging (MRI)-Guided Differential-Dose Prostate Brachytherapy
Status: Enrolling
Updated:  1/5/2017
Saint Lukes-Roosevelt Hospital Center
mi
from
New York, NY
Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy
Phase I/II Evaluation Magnetic Resonance Imaging (MRI)-Guided Differential-Dose Prostate Brachytherapy
Status: Enrolling
Updated: 1/5/2017
Saint Lukes-Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Status: Enrolling
Updated:  1/5/2017
Florida Cancer Specialists
mi
from
Fort Myers, FL
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Status: Enrolling
Updated: 1/5/2017
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Status: Enrolling
Updated:  1/5/2017
Florida Cancer Center
mi
from
St. Petersburg, FL
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Status: Enrolling
Updated: 1/5/2017
Florida Cancer Center
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Status: Enrolling
Updated:  1/5/2017
Oncology Hematology Care
mi
from
Cincinnati, OH
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Status: Enrolling
Updated: 1/5/2017
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Status: Enrolling
Updated:  1/5/2017
Tennessee Oncology PLLC
mi
from
Chattanooga, TN
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Status: Enrolling
Updated: 1/5/2017
Tennessee Oncology PLLC
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Status: Enrolling
Updated:  1/5/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Status: Enrolling
Updated: 1/5/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Internet-based System for Cancer Patients to Self-report Toxicity
Pilot Study of STAR, an Internet-based System for Cancer Patients to Self-report Toxicity Symptoms, Performance Status, and Quality of Life
Status: Enrolling
Updated:  1/9/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Internet-based System for Cancer Patients to Self-report Toxicity
Pilot Study of STAR, an Internet-based System for Cancer Patients to Self-report Toxicity Symptoms, Performance Status, and Quality of Life
Status: Enrolling
Updated: 1/9/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
A Phase II Trial of Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer Previously Treated With Docetaxel
Status: Enrolling
Updated:  1/23/2017
Weill-Cornell Medical College
mi
from
New York, NY
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
A Phase II Trial of Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer Previously Treated With Docetaxel
Status: Enrolling
Updated: 1/23/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Health Interventions in Men Undergoing Radical Prostatectomy
Health Interventions in Men Undergoing Radical Prostatectomy- A Randomized Controlled Clinical Trial
Status: Enrolling
Updated:  1/25/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Health Interventions in Men Undergoing Radical Prostatectomy
Health Interventions in Men Undergoing Radical Prostatectomy- A Randomized Controlled Clinical Trial
Status: Enrolling
Updated: 1/25/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  2/1/2017
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 2/1/2017
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  2/1/2017
University of Chicago
mi
from
Chicago, IL
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 2/1/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  2/1/2017
North Shore University Health System
mi
from
Evanston, IL
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 2/1/2017
North Shore University Health System
mi
from
Evanston, IL
Click here to add this to my saved trials
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  2/1/2017
Ingalls Memorial Hospital
mi
from
Harvey, IL
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 2/1/2017
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  2/1/2017
Illinois Cancer Care
mi
from
Peoria, IL
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 2/1/2017
Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  2/1/2017
National University Hospital
mi
from
Singapore,
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 2/1/2017
National University Hospital
mi
from
Singapore,
Click here to add this to my saved trials
Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance
Assessment of the Biological Effect of Autophagic Inhibition With Hydroxychloroquine in Prostate Cancer
Status: Enrolling
Updated:  2/1/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance
Assessment of the Biological Effect of Autophagic Inhibition With Hydroxychloroquine in Prostate Cancer
Status: Enrolling
Updated: 2/1/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
Massachusetts General Hospital Mass Gen 3
mi
from
Boston, MA
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
Massachusetts General Hospital Mass Gen 3
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
Cancer Institute of New Jersey SC
mi
from
New Brunswick, NJ
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
Cancer Institute of New Jersey SC
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
Thomas Jefferson University, Dept. of Phsyciatry & Neurology Thomas Jefferson
mi
from
Philadelphia, PA
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
Thomas Jefferson University, Dept. of Phsyciatry & Neurology Thomas Jefferson
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
University of Utah / Huntsman Cancer Institute Huntsman 3
mi
from
Salt Lake City, UT
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
University of Utah / Huntsman Cancer Institute Huntsman 3
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
University of Wisconsin Clinical Science Center
mi
from
Madison, WI
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
University of Wisconsin Clinical Science Center
mi
from
Madison, WI
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Bruxelles,
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Bruxelles,
Click here to add this to my saved trials
Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer
Randomized Study of Sunphenon Decaffeinated Capsules in Men With Low-Risk Prostate Cancer on Active Surveillance
Status: Enrolling
Updated:  3/2/2017
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer
Randomized Study of Sunphenon Decaffeinated Capsules in Men With Low-Risk Prostate Cancer on Active Surveillance
Status: Enrolling
Updated: 3/2/2017
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Tucson, AZ
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Atherton, CA
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Atherton, CA
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
La Mesa, CA
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
La Mesa, CA
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Long Beach, CA
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
San Diego, CA
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Denver, CO
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Englewood, CO
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Englewood, CO
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
New Britain, CT
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
New Britain, CT
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Aventura, FL
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Aventura, FL
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Naples, FL
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Jeffersonville, IN
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Shreveport, LA
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Annapolis, MD
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Annapolis, MD
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Baltimore, MD
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Brick, NJ
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Brick, NJ
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Albuquerque, NM
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Garden City, NY
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Garden City, NY
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
New York, NY
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Germantown, TN
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Carrollton, TX
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Carrollton, TX
Click here to add this to my saved trials
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials